Enlivex Therapeutics (ENLV) Short Interest Ratio & Short Volume → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free ENLV Stock Alerts $1.50 -0.02 (-1.32%) (As of 05/10/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Enlivex Therapeutics Short Interest DataCurrent Short Volume263,200 sharesPrevious Short Volume278,700 sharesChange Vs. Previous Month-5.56%Dollar Volume Sold Short$439,544.00Short Interest Ratio / Days to Cover1.5Last Record DateApril 30, 2024Outstanding Shares18,600,000 sharesPercentage of Shares Shorted1.42%Today's Trading Volume40,879 sharesAverage Trading Volume219,019 sharesToday's Volume Vs. Average19% Short Selling Enlivex Therapeutics ? Sign up to receive the latest short interest report for Enlivex Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatENLV Short Interest Over TimeENLV Days to Cover Over TimeENLV Percentage of Float Shorted Over Time Ad Colonial MetalsCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar. For one main reason.In answer to this issue, we have released a Special Report to the public. Enlivex Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/2024263,200 shares $439,544.00 -5.6%N/A1.5 $1.67 4/15/2024278,700 shares $362,310.00 +17.9%N/A1.6 $1.30 3/31/2024236,400 shares $895,956.00 -9.6%N/A2.7 $3.79 3/15/2024261,500 shares $1.07 million +15.4%N/A2.4 $4.11 2/29/2024226,600 shares $703,593.00 +51.2%N/A2.2 $3.11 2/15/2024149,900 shares $481,179.00 -6.6%N/A1.6 $3.21 Get the Latest News and Ratings for ENLV and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Enlivex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/2024160,500 shares $449,400.00 -13.7%N/A1.9 $2.80 1/15/2024185,900 shares $533,533.00 +32.5%N/A2.3 $2.87 12/31/2023140,300 shares $378,810.00 +36.0%N/A1.8 $2.70 12/15/2023103,200 shares $145,512.00 -6.3%N/A1.9 $1.41 11/30/2023110,100 shares $202,584.00 -0.9%N/A3.5 $1.84 11/15/2023111,100 shares $194,425.00 -6.2%N/A3.6 $1.75 10/31/2023118,400 shares $157,472.00 +13.1%N/A3.9 $1.33 10/15/2023104,700 shares $147,627.00 -8.1%N/A4.1 $1.41 9/30/2023113,900 shares $179,962.00 +4.4%N/A4.5 $1.58 9/15/2023109,100 shares $206,199.00 +3.4%N/A4.2 $1.89 8/31/2023105,500 shares $252,145.00 -9.3%N/A4.8 $2.39 8/15/2023116,300 shares $303,543.00 +2.4%N/A5.1 $2.61 7/31/2023113,600 shares $290,816.00 +8.6%N/A4.9 $2.56 7/15/2023104,600 shares $248,948.00 +2.5%N/A4.8 $2.38 6/30/2023102,100 shares $268,247.33 -20.2%N/A3.6 $2.63 6/15/2023128,000 shares $362,240.00 +5.6%N/A3.6 $2.83 5/31/2023121,200 shares $316,332.00 -5.8%N/A3.5 $2.61 5/15/2023128,700 shares $359,073.00 -1.2%N/A3.8 $2.79 4/30/2023130,200 shares $369,768.00 -4.6%N/A3.7 $2.84 4/15/2023136,400 shares $396,924.00 -15.7%N/A3.6 $2.91 3/31/2023161,700 shares $588,588.00 +0.5%N/A4.3 $3.64 3/15/2023160,900 shares $577,631.00 -1.3%N/A5.9 $3.59 2/28/2023163,000 shares $652,000.00 +0.9%N/A5.7 $4.00 2/15/2023161,500 shares $673,455.00 -8.8%N/A5.5 $4.17 1/31/2023177,100 shares $775,698.00 -2.9%N/A5.8 $4.38 1/15/2023182,300 shares $796,505.16 -4.8%N/A6.9 $4.37 12/30/2022191,400 shares $753,637.50 -0.5%N/A7.8 $3.94 12/15/2022192,400 shares $779,220.00 -11.5%N/A9.2 $4.05 11/30/2022217,500 shares $996,998.25 +16.9%N/A9 $4.58 11/15/2022186,000 shares $894,660.00 +0.1%N/A6.9 $4.81 10/31/2022185,800 shares $797,082.00 -3.8%N/A6.6 $4.29 10/15/2022193,100 shares $805,227.00 +1.2%N/A5.4 $4.17 9/30/2022190,900 shares $811,325.00 +4.5%N/A4.4 $4.25 9/15/2022182,700 shares $959,175.00 -5.4%N/A3.9 $5.25Trump’s “Tax Free” Retirement Strategy (Ad)Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… ENLV Short Interest - Frequently Asked Questions What is Enlivex Therapeutics' current short interest? Short interest is the volume of Enlivex Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 30th, traders have sold 263,200 shares of ENLV short. Learn More on Enlivex Therapeutics' current short interest. What is a good short interest ratio for Enlivex Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ENLV shares currently have a short interest ratio of 2.0. Learn More on Enlivex Therapeutics's short interest ratio. Is Enlivex Therapeutics' short interest increasing or decreasing? Enlivex Therapeutics saw a decline in short interest in April. As of April 30th, there was short interest totaling 263,200 shares, a decline of 5.6% from the previous total of 278,700 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Enlivex Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Enlivex Therapeutics: NRx Pharmaceuticals, Inc. (6.36%), Theratechnologies Inc. (0.10%), Aprea Therapeutics, Inc. (1.90%), Acasti Pharma Inc. (0.02%), Acurx Pharmaceuticals, Inc. (4.67%), Daré Bioscience, Inc. (0.29%), Unity Biotechnology, Inc. (2.16%), Lipocine Inc. (3.49%), Biora Therapeutics, Inc. (4.52%), Viracta Therapeutics, Inc. (2.54%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Enlivex Therapeutics stock? Short selling ENLV is an investing strategy that aims to generate trading profit from Enlivex Therapeutics as its price is falling. ENLV shares are trading down $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Enlivex Therapeutics? A short squeeze for Enlivex Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ENLV, which in turn drives the price of the stock up even further. How often is Enlivex Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ENLV, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: NRx Pharmaceuticals Short Squeeze Theratechnologies Short Squeeze Aprea Therapeutics Short Squeeze Acasti Pharma Short Squeeze Acurx Pharmaceuticals Short Squeeze Daré Bioscience Short Squeeze Unity Biotechnology Short Squeeze Lipocine Short Squeeze Biora Therapeutics Short Squeeze Viracta Therapeutics Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ENLV) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsThe Crypto 9-5 Escape PlanCrypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithGold Set to EXPLODE!Gold Safe ExchangeCollapse of the Petrodollar Colonial Metals[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsRSVP: Charles Payne’s Cash Flow WorkshopUnstoppable Prosperity